Altre lingue Tenax Therapeutics, Inc.

Azioni

TENX

US88032L6056

Tempo differito Nasdaq Altri mercati azionari 19:22:09 19/04/2024			Variaz. 5gg	Var. 1 gen.
3,69 ^USD	+0,27%		-1,86%	-83,20%

28/03	Tenax Therapeutics, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI
28/03	Tenax Therapeutics, Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	09/04
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	28/03
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Tenax Therapeutics to Present at the 36th Annual Roth Conference	12/03
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	29/02
Tenax Therapeutics Secures Global Rights for Levosimendan	20/02
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	20/02
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	20/02
Top Midday Decliners	08/02
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	08/02
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	08/02
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	08/02
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	08/02
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	08/02
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	08/02
Sector Update: Health Care Stocks Gain Late Afternoon	06/02
Sector Update: Health Care	06/02
Top Midday Gainers	06/02
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	06/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tenax Therapeutics, Inc.

Azioni

TENX

US88032L6056

Altre lingue

Filtri